68
Participants
Start Date
March 28, 2019
Primary Completion Date
March 26, 2022
Study Completion Date
March 28, 2022
JNJ-67571244
JNJ-67571244 will be administered.
Hosp Univ Vall D Hebron, Barcelona
NYU Hematology Associates, New York
Hosp Univ Fund Jimenez Diaz, Madrid
Levine Cancer Institute, Carolinas HealthCare System, Charlotte
Clinica Univ. de Navarra, Pamplona
Sarah Cannon Research Institute, Nashville
Hosp. Virgen Del Rocio, Seville
Universitätsklinikum Münster; Med. Klinik A - Germany, Münster
Barbara Ann Karmanos Cancer Institute, Detroit
MD Anderson Cancer Center, Houston
Klinikum der Universitaet Muenchen, München
Fred Hutchinson Cancer Research Center, Seattle
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Hackensack University Medical Center, Hackensack
Universitaetsklinikum Leipzig, Leipzig
Hosp Clinic de Barcelona, Barcelona
Janssen Research & Development, LLC
INDUSTRY